Biotech Battle Royale: Replimune’s High-Stakes Market Clash

Replimune US76029N1063

A dramatic financial confrontation is unfolding around Replimune Group, where hedge funds betting against the company face off against institutional investors building substantial positions. This collision of opposing market philosophies creates a powder keg scenario that could trigger significant price movements in the biotech firm’s shares.

The investment landscape reveals overwhelming confidence from major financial institutions, with institutional ownership reaching a remarkable 92.53% of Replimune’s outstanding shares. Capital flows further demonstrate this conviction, as institutional inflows totaled $246.73 million over the past year, dramatically outpacing outflows of just $86.43 million.

Several asset managers have made particularly aggressive moves to increase their exposure:

• Braidwell Read more...